Cardiovascular disease progression and its subsequent effect on morbity and mortality in australian patients with chronic kidney disease: a 10 year follow up

Not Applicable

Active, not recruiting

• Conditions: Chronic kidney disease; Cardiovascular disease; Renal and Urogenital - Kidney disease; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12613000260729
• Lead Sponsor: A/Prof Tony Stanton, Director

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-03-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

All participants enrolled in original Landmark 1 trial

Exclusion Criteria

Not enrolled in original Landmark 1 trial

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality. Date of death and whether cardiovascular or non-cardiovascular cause will be requested from the ANZDATA database custodian.[Ten years from study enrollment in the Landmark 1 trial];Details of major cardiac adverse events will also be obtained to the 10 year point from the Nephrology Database at the Princess Alexandra Hospital. Such events would include, myocardial infarction, heart failure, cardiac arrythmias, acute coronary syndrome.[Ten years from enrollment in original Landmark 1 trial]

Secondary Outcome Measures

Name	Time	Method
Complications related to chronic kidney disease will mainly focus on the incidence of kidney transplant after kidney failure. This data will be obtained from the ANZDATA database.[Ten years from enrollment in original Landmark1 trial]